Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study to Evaluate Acute and Short-term Efficacy of Digest Gold on Postprandial Abdominal Distension and Subjective Bloating in Healthy Adults

21 september 2026 uppdaterad av: Enzymedica

A Randomized, Triple-blind, Placebo-controlled, Cross-over Study to Evaluate Acute and Short-term Efficacy of Digest Gold on Postprandial Abdominal Distension and Subjective Bloating in Healthy Adults

The goal of this clinical trial is to investigate the acute and short-term efficacy of Digest Gold on postprandial abdominal distension and subjective bloating in healthy adults. The main question it aims to answer is what is the difference between Digest Gold and placebo in time-to-relief of subjective bloating (time = 0 -120 minutes postprandial), as assessed by the bloating Likert scale?Researchers will compare Digest Gold to a placebo to see its effects on postprandial abdominal distension and bloating. Participants will:

  • Consume Digest Gold and a placebo.
  • Have height, weight, and waist circumference measured.
  • Have blood pressure and heart rate measured.
  • Provide blood samples.
  • Provide a fecal sample.
  • Complete study questionnaires assessing gastrointestinal symptoms and subjective bloating.
  • Record their daily food intake.
  • Complete a breath test to assess gastrointestinal parameters.

Studieöversikt

Status

Har inte rekryterat ännu

Studietyp

Interventionell

Inskrivning (Beräknad)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Males and females aged 18 years and older

  2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,

    Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:

    • Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    • Double-barrier method
    • Intrauterine devices
    • Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
    • Vasectomy of partner at least 6 months prior to screening
    • Abstinence and agrees to use contraception if planning on becoming sexually active during the study
  3. Self-reported post-meal bloating or abdominal distension at least one day per week AND confirmation of a history of bloating or abdominal distension following consumption of meals similar to the study-specific standardized meal

  4. Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits

  5. Agrees to avoid moderate-vigorous exercise (cardio or strength training) or strenuous physical activity 12 hours prior to clinic visits

  6. Agrees to avoid nonsteroidal anti-inflammatory drugs (NSAIDs) 24 hours prior to clinic visits (Section 7.3.2)

  7. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study

  8. Provided voluntary, written, informed consent to participate in the study

  9. Healthy as determined by medical history and laboratory results as assessed by the Medical Doctor (MD)

Exclusion Criteria:

  1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
  2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product (IP), placebo, or standardized meal ingredients (e.g., gluten intolerance)
  3. Current or history of any significant diseases of the gastrointestinal tract or digestive disorders (e.g., celiac disease, inflammatory bowel disease, functional constipation, unstable gastroesophageal reflux disease, unstable gallstones), as assessed by the MD
  4. Colonoscopy within 14 days of baseline or scheduled colonoscopy during the study period
  5. Unstable metabolic disease or chronic diseases as assessed by the MD
  6. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the MD (See Section 7.3)
  7. Type I or Type II diabetes
  8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the MD on a case by-case basis
  9. History of or current diagnosis with kidney and/or liver diseases as assessed by the MD on a case by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
  10. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the MD
  11. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the MD
  12. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
  13. Individuals with an autoimmune disease or are immune compromised as assessed by the MD
  14. Self-reported confirmation of a Human Immunodeficiency Virus (HIV)-, Hepatitis B- and/or C-positive diagnosis as assessed by the MD
  15. Self-reported confirmation of blood/bleeding disorders as assessed by the MD
  16. Use of prescribed medical cannabinoid products
  17. Chronic use of cannabinoid products (>2 times/week). Occasional users will be required to washout and abstain for the duration of the study period
  18. Regular use of tobacco or nicotine products in the past six months, as assessed by the MD. Occasional users will be required to washout and abstain for the duration of the study period
  19. Alcohol intake average of >2 standard drinks per day as assessed by the MD
  20. Alcohol or drug abuse within the last 12 months
  21. Current use of prescribed and/or Over-the-Counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Section 7.3)
  22. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
  23. Participation in other clinical research studies 30 days prior to baseline, as assessed by the MD
  24. Individuals who are unable to give informed consent
  25. Any other condition or lifestyle factor, that, in the opinion of the MD, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Digest Gold

At Visit 1 (Day 1 of Period 1) and Visit 3 (Day 1 of Period 2), study staff will provide participants with one capsule of study product with water to be consumed with the first bite of the standardized meal. Starting on Day 2 of Period 1, participants will be instructed to take one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner) until Day 6 of Period 1. After a minimum 10-day wash out, participants will return to the study site and will be provided with one capsule of study product to be taken with water at the first bite of the standardized meal. Participants will be instructed to resume daily consumption of the alternate study product (one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner)) from Day 2 until Day 6 of Period 2.

At Visit 1 (Day 1 of Period 1) and Visit 3 (Day 1 of Period 2), study staff will provide participants with one capsule of study product with water to be consumed with the first bite of the standardized meal. Starting on Day 2 of Period 1, participants will be instructed to take one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner) until Day 6 of Period 1. After a minimum 10-day wash out, participants will return to the study site and will be provided with one capsule of study product to be taken with water at the first bite of the standardized meal. Participants will be instructed to resume daily consumption of the alternate study product (one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner)) from Day 2 until Day 6 of Period 2.

Placebo-jämförare: Placebo

At Visit 1 (Day 1 of Period 1) and Visit 3 (Day 1 of Period 2), study staff will provide participants with one capsule of study product with water to be consumed with the first bite of the standardized meal. Starting on Day 2 of Period 1, participants will be instructed to take one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner) until Day 6 of Period 1. After a minimum 10-day wash out, participants will return to the study site and will be provided with one capsule of study product to be taken with water at the first bite of the standardized meal. Participants will be instructed to resume daily consumption of the alternate study product (one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner)) from Day 2 until Day 6 of Period 2.

At Visit 1 (Day 1 of Period 1) and Visit 3 (Day 1 of Period 2), study staff will provide participants with one capsule of study product with water to be consumed with the first bite of the standardized meal. Starting on Day 2 of Period 1, participants will be instructed to take one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner) until Day 6 of Period 1. After a minimum 10-day wash out, participants will return to the study site and will be provided with one capsule of study product to be taken with water at the first bite of the standardized meal. Participants will be instructed to resume daily consumption of the alternate study product (one capsule three times a day with food (at the beginning of breakfast, lunch, and dinner)) from Day 2 until Day 6 of Period 2.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The difference between Digest Gold and placebo in time-to-relief of subjective bloating (time = 0 - 120 minutes postprandial)
Tidsram: Day 1

The difference between Digest Gold and placebo in time-to-relief of subjective bloating (time = 0 - 120 minutes postprandial), as assessed by the bloating Likert scale. A four-point Likert scale (absent - 0, mild - 1, moderate - 2, or severe - 3) will be used to measure gas and bloating. A higher score means more severe bloating.

Day 1

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The difference in change between Digest Gold and placebo in abdominal distension
Tidsram: Pre-dose to time = 15, 30, 60, and 120 minutes postprandial at Day 1

The difference in change between Digest Gold and placebo from pre-dose to time = 15, 30, 60, and 120 minutes postprandial at Day 1 in abdominal distension, as assessed by waist circumference

Pre-dose to time = 15, 30, 60, and 120 minutes postprandial at Day 1
The difference in change between Digest Gold and placebo in subjective bloating
Tidsram: Pre-dose to time = 15, 30, 60, and 120 minutes postprandial at Day 1

The difference in change between Digest Gold and placebo from pre-dose to time = 15, 30, 60, and 120 minutes postprandial at Day 1 in subjective bloating, as assessed by the gas and bloating Likert scales. A four-point Likert scale (absent - 0, mild - 1, moderate - 2, or severe - 3) will be used to measure gas and bloating. A higher score means more severe bloating.

Pre-dose to time = 15, 30, 60, and 120 minutes postprandial at Day 1
The difference in postprandial waist circumference area under the curve (AUC₀-₁₂₀ minutes) between Digest Gold and placebo
Tidsram: Day 1

The difference in postprandial waist circumference area under the curve (AUC₀-₁₂₀ minutes) between Digest Gold and placebo at Day 1.

Day 1
The difference in maximum postprandial change in waist circumference from the pre-meal measurement between Digest Gold and placebo at Day 1.
Tidsram: Day 1

The difference in maximum postprandial change in waist circumference from the pre-meal measurement between Digest Gold and placebo at Day 1.

Day 1
The difference in change in breath methane and hydrogen between Digest Gold and placebo
Tidsram: Pre-dose to time = 60 and 120 minutes postprandial at Day 1

The difference in change in breath methane and hydrogen between Digest Gold and placebo from pre-dose to time = 60 and 120 minutes postprandial at Day 1, as assessed by the FoodMarble Breath Tester

Pre-dose to time = 60 and 120 minutes postprandial at Day 1
The difference in postprandial breath methane and hydrogen area under the curve (AUC₀-₁₂₀ minutes) at Day 1 between Digest Gold and placebo
Tidsram: Day 1

The difference in postprandial breath methane and hydrogen area under the curve (AUC₀-₁₂₀ minutes) at Day 1 between Digest Gold and placebo, as assessed by the FoodMarble Breath Tester.

Day 1
The difference between Digest Gold and placebo in time-to-relief of subjective gas
Tidsram: Day 1

The difference between Digest Gold and placebo in time-to-relief of subjective gas, as assessed by the gas Likert scale at Day 1. A four-point Likert scale (absent - 0, mild - 1, moderate - 2, or severe - 3) will be used to measure gas and bloating. A higher score means more severe gas.

Day 1
Difference in Change in Glucose Concentration from Pre-Dose to 15, 30, 60, and 120 Minutes Postprandial Between Digest Gold and Placebo on Day 1
Tidsram: Day 1

The difference in change between Digest Gold and placebo from pre-dose to time = 15, 30, 60 and 120 minutes postprandial at Day 1 in glucose.

Day 1
Difference in Change in Insulin Concentration from Pre-Dose to 15, 30, 60, and 120 Minutes Postprandial Between Digest Gold and Placebo on Day 1
Tidsram: Day 1

The difference in change between Digest Gold and placebo from pre-dose to time = 15, 30, 60 and 120 minutes postprandial at Day 1 in insulin.

Day 1
Difference in Change in Triglyceride Concentration from Pre-Dose to 15, 30, 60, and 120 Minutes Postprandial Between Digest Gold and Placebo on Day 1
Tidsram: Day 1

The difference in change between Digest Gold and placebo from pre-dose to time = 15, 30, 60 and 120 minutes postprandial at Day 1 in triglycerides.

Day 1
Difference in Change in Total Amino Acid Concentration from Pre-Dose to 15, 30, 60, and 120 Minutes Postprandial Between Digest Gold and Placebo on Day 1
Tidsram: Day 1

The difference in change between Digest Gold and placebo from pre-dose to time = 15, 30, 60 and 120 minutes postprandial at Day 1 in total amino acids.

Day 1
The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in abdominal distension
Tidsram: Day 1 to Day 7

The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in abdominal distension, as assessed by waist circumference.

Day 1 to Day 7
The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in breath methane and hydrogen
Tidsram: Day 1 to Day 7

The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in breath methane and hydrogen, as assessed by the FoodMarble Breath Tester.

Day 1 to Day 7
The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in Gastrointestinal symptoms
Tidsram: Day 1 to Day 7

The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in Gastrointestinal symptoms, as assessed by the modified Gastrointestinal Symptom Rating Scale (GSRS). The modified GSRS includes 14 questions with a four-point Likert scale from 0-3, with lower scores representing better gastrointestinal symptoms.

Day 1 to Day 7
The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in gas and bloating
Tidsram: Day 1 to Day 7

The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in Gas and bloating, as assessed by Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms (PROMIS-GI) Gas and Bloating Scale 13a. All items are administered using a 5-point categorical response scale. A higher score denotes more gastrointestinal symptoms.

Day 1 to Day 7
The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in quality of life
Tidsram: Day 1 to Day 7

The difference between Digest Gold and placebo in the change from Day 1 (pre-supplementation) to Day 7 following 6 days of supplementation in Quality of life, as assessed by the RAND 36-Item Short Form Health Survey (SF-36). The scores range from 0 to 100 where higher scores indicate a better state of health.

Day 1 to Day 7
The difference between Digest Gold and placebo in the daily postprandial area under the curve (AUC) during the supplementation period (Day 1 to 6) for abdominal distension
Tidsram: Day 1 to Day 6

The difference between Digest Gold and placebo in the daily postprandial area under the curve (AUC) during the supplementation period (Day 1 to 6) for abdominal distension as assessed by waist circumference

Day 1 to Day 6
The difference between Digest Gold and placebo in the daily postprandial area under the curve (AUC) during the supplementation period (Day 1 to 6) for breath methane and hydrogen
Tidsram: Day 1 to Day 6

The difference between Digest Gold and placebo in the daily postprandial area under the curve (AUC) during the supplementation period (Day 1 to 6) for breath methane and hydrogen, as assessed by FoodMarble Breath Test

Day 1 to Day 6

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in gut microbiota composition between Digest Gold and placebo from pre-supplementation to after 7 days of supplementation
Tidsram: Day 1 to Day 7

Change in gut microbiota composition between Digest Gold and placebo from pre-supplementation to after 7 days of supplementation, as assessed by fecal microbiome analysis

Day 1 to Day 7
Incidence of post-emergent adverse events (AE)
Tidsram: Day 1 to Day 7

Incidence of post-emergent adverse events (AE)

Day 1 to Day 7
Clinically relevant changes in blood pressure
Tidsram: Day 1 to Day 7

Clinically relevant changes in blood pressure (mmHG)

Day 1 to Day 7
Clinically relevant changes in heart rate
Tidsram: Day 1 to Day 7

Clinically relevant changes in heart rate (beats per minute)

Day 1 to Day 7

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 september 2026

Primärt slutförande (Beräknad)

1 november 2026

Avslutad studie (Beräknad)

1 november 2026

Studieregistreringsdatum

Först inskickad

15 september 2026

Först inskickad som uppfyllde QC-kriterierna

15 september 2026

Första postat (Faktisk)

21 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

23 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 26EMKCR01

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera